Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking

doi:10.1093/ejechocard/jen160

European Journal of Echocardiography Advance Access originally published online on May 7, 2008
European Journal of Echocardiography 2008 9(6):803-808; doi:10.1093/ejechocard/jen160

This Article

	Full Text
	FREE Full Text (PDF)
	All Versions of this Article: 9/6/803 most recent jen160v1
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions
	Disclaimer

Google Scholar

	Articles by Rasmussen, V. G.
	Articles by Egeblad, H.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Rasmussen, V. G.
	Articles by Egeblad, H.

Social Bookmarking

	What's this?

Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking

Vibeke Guldbrand Rasmussen¹^,*, Steen Hvitfeldt Poulsen¹, Erik Dupont², Karen Østergaard², Gholamhossein Safikhany³ and Henrik Egeblad¹

¹ Department of Cardiology, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark
² Department of Neurology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark
³ Department of Neurology, Holstebro Hospital, DK-7500 Holstebro, Denmark

Received 9 January 2008; accepted after revision 12 April 2008; online publish-ahead-of-print 7 May 2008.

^* Corresponding author. Tel: +45 89496234; fax: +45 89496009. E-mail address: vibeke.guldbrand{at}ki.au.dk

Abstract

Aims: Ergot-derived dopamine agonists (EDDA) induce fibrotic heartvalve disease. We aimed to investigate whether EDDA treatmentalso affects left ventricular (LV) function.

Methods and results: Myocardial function was evaluated in 110 Parkinson patients[mean age (63.4 ± 9.0 years)] treated for at least 6months with either EDDA (n = 71) or non-EDDA (n = 39). LV ejectionfraction did not differ between EDDA and non-EDDA patients [63± 4% vs. 65 ± 4% (ns)]. There was no differencein prevalence of diastolic dysfunction between EDDA and non-EDDApatients [7% vs. 8% (ns)]. Finally, averaged LV systolic myocardialstrain and longitudinal displacement analysed by means of two-dimensionalspeckle tracking showed no difference between EDDA and non-EDDApatients [strain: 19 ± 3% vs. 19 ± 2% (ns) andlongitudinal displacement: 12 ± 2 mm vs. 12 ±2 mm (ns)]. Elevated p-NT-proBNP was found in 38% of EDDA patientsand in 59% of non-EDDA patients (ns).

Conclusion: In contrast to the well-established association between EDDAtreatment and valvular fibrosis, EDDA did not have a detectableadverse impact on myocardial systolic and diastolic function.

Keywords: Myocardial function; Fibrosis; Ergolines; Dopamine agonists

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us What's this?

This article has been cited by other articles:

S. Droogmans, B. Roosens, B. Cosyns, C. Degaillier, S. Hernot, C. Weytjens, C. Garbar, V. Caveliers, M. Pipeleers-Marichal, P. R. Franken, et al.
Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1940 - H1948.
[Abstract] [Full Text] [PDF]